Radioimmunotherapy in non-Hodgkin's lymphoma: Trials of yttrium 90-labeled ibritumomab tiuxetan and beyond

Clinical Lymphoma

Volumn 5, Issue SUPPL. 1, 2004, Pages

  Evens, Andrew M ^a   Gordon, Leo I ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Cytopenia; Iodine 1 131 tositumomab; Motexafin gadolinium; Quality of life; Radioimmunoconjugates; Rituximab

Indexed keywords

ANTHRACYCLINE; CD20 ANTIGEN; CD59 ANTIGEN; DECAY ACCELERATING FACTOR; GADOLINIUM TEXAPHYRIN; IBRITUMOMAB TIUXETAN; IODINE 131; MONOCLONAL ANTIBODY; PENTETIC ACID; RADIOISOTOPE; RITUXIMAB; TOSITUMOMAB I 131; YTTRIUM 90;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BONE MARROW TOXICITY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DISEASE COURSE; DOSIMETRY; DRUG ABSORPTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; GONADAL DISEASE; HEMATOLOGIC DISEASE; HUMAN; IMMUNOLOGY; ISOTOPE LABELING; LONG TERM CARE; MOLECULAR BIOLOGY; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; OUTCOMES RESEARCH; PREDICTION; QUALITY OF LIFE; RADIOIMMUNOTHERAPY; THROMBOCYTOPENIA;

EID: 7744227600     PISSN: 15269655     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2004.s.003     Document Type: Article

References (53)

1. Foon KA. Advances in cancer: monoclonal antibody therapy of hematologic malignancies. N J Med 1987; 84:269-274.
2. Wiemann B, Starnes CO. Coley's toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol Ther 1994; 64:529-564.
3. Gresser IA Chekhov, MD, and Coley's toxins. N Engl J Med 1987; 317:457.
4. Silverstein AM. Paul Ehrlich's passion: the orgins of his receptor immunology. Cell Immunol 1999; 194:213-221.
5. Schwartz RS. Paul Ehrlich's magic bullets. N Engl J Med 2004; 350:1079-1080.
6. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256:495-497.
7. Miller RA, Maloney DG, McKillop J, et al. In vivo effects of murine hybridoma. monoclonal antibody in a patient with T-cell leukemia. Blood 1981; 58:78-86.
8. Miller RA, Maloney DG, Warnke R, et al. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med 1982; 306:517-522.
9. Miller RA, Maloney D, Levy R. Monoclonal antibodies in the treatment of human leukemias and lymphomas: applications of flow cyrometry. Ann N Y Acad Sci 1984; 428:49-56.
10. Press OW, Eary JF, Badger CC, et al. Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody. J Clin Oncol 1989; 7:1027-1038.
11. Press OW, Appelbaum F, Ledbetter JA, et al. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood 1987; 69:584-591.
12. Thielemans K, Maloney DG, Meeker T, et al. Strategies for production of monoclonal anti-idiotype antibodies against human B cell lymphomas. J Immunol 1984; 133:495-501.
13. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83:435-445.
14. Renner C, Trumper L, Pfreundschuh M. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma: recent results and future prospects. Leukemia 1997; 11 (suppl 2):55s-59s.
15. Golay J, Zaffaroni L, Vaccari T, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000; 95:3900-3908.
16. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymerphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003; 21:3940-3947.
17. Farag SS, Flinn IW, Modali R, et al. Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia. Blood 2004; 103:1472-1474.
18. Bellosillo B, Villamor N, Lopez-Guillermo A, et al. Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species. Blood 2001; 98:2771-2777.
19. DeNardo GL, O'Donnell RT, Oldham RK, et al. A revolution in the treatment of non-Hodgkin's lymphoma. Cancer Biother Radiopharm 1998; 13:213-223.
20. DiJoseph JF, Armellino DC, Boghaert ER, et al. Antibody-targeted chemotherapy with CMC-544: A CD22-targeted immunoconjugate of calicheamicin for the treatment of B lymphoid malignancies. Blood 2004; 103:1807-1814.
21. Chinn PC, Leonard JE, Rosenberg J, et al. Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma. Int J Oncol 1999; 15:1017-1025.
22. White CA, Wiseman G. Conventional treatments for non-Hodgkin's lymphoma: the need for new therapies. J Nucl Med 1999; 40:1967-1968.
23. DeNardo GL, DeNardo SJ, Shen S, et al. Factors affecting 131I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia. J Nucl Med 1999; 40:1317-1326.
24. Gates VL, Carey JE, Siegel JA, et al. Nonmyeloablative iodine-131 anti-B1 radioimmunotherapy as outpatient therapy. J Nucl Med 1998; 39:1230-1236.
25. Kaminski MS, Estes J, Zasadny KR, et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 2000; 96:1259-1266.
26. Kaminski MS, Zasadny KR, Francis IR, et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 1996; 14:1974-1981.
27. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002; 20:2453-2463.
28. Gordon LI, Witzig TE, Wiseman GA, et al. Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma. Semin Oncol 2002; 29:87-92.
29. DeNardo GL, O'Donnell RT, Shen S, et al. Radiation dosimetry for 90Y-2IT-BAD-Lym-1 extrapolated from pharmacokinetics using 111 In-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma. J Nucl Med 2000; 41:952-958.
30. Wiseman GA, White CA, Witzig TE, et al. Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with Zevalin, a 90Y-labeled anti-CD20 monoclonal antibody. Clin Cancer Res 1999; 5:3281s-3286s.
31. Wahl RL, Kroll S, Zasadny KR. Patient-specific whole-body dosimetry: principles and a simplified method for clinical implementation. J Nucl Med 1998; 39:14S-20S.
32. Juweid ME, Stadtmauer E, Hajjar G, et al. Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma. Clin Cancer Res 1999; 5:3292s-3303s.
33. Siegel JA. Revised Nuclear Regulatory Commission regulations for release of patients administered radioactive materials: outpatient iodine-131 anti-B1 therapy. J Nucl Med 1998; 39:28S-33S.
34. Ryan MT, Spicer KM, Frei-Lahr D, et al. Health physics consequences of outpatient treatment of non-Hodgkin's lymphoma with 131I-radiolabeled anti-B1 antibody. Health Phys 2000; 79:52s-55s.
35. Wiseman GA, Kornmehl E, Leigh B, et al. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. J Nucl Med 2003; 44:465-474.
36. Witzig TE, White CA, Wiseman GA, et al. Phase I/II trial of IDEC-Y2BB radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 1999; 17:3793-3803.
37. Wiseman GA, Gordon LI, Multani PS, et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 2002; 99:4336-4342.
38. Knox SJ, Goris ML, Trisler K, et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 1996; 2:457-470.
39. Witzig TE, White CA, Gordon LI, et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol 2003; 21:1263-1270.
40. Travis LB, Curtis RE, Stovall M, et al. Risk of leukemia following treatment for non-Hodgkin's lymphoma. J Natl Cancer Inst 1994; 86:1450-1457.
41. Gordon LI. Practical considerations and radiation safety in radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin). Semin Oncol 2003; 30:23-28.
42. Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 1997; 34:13-19.
43. Cella D, Webster KA. Quality of life and treatment value in the management of hematologic malignancies. Semin Oncol 1999; 26:34-42.
44. Press OW, Eary JF, Gooley T, et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 2000; 96:2934-2942.
45. Winter JN, Inwards D, Erwin W, et al. Phase I trial combining 90Y Zevalin and high-dose BEAM chemotherapy with hematopoietic progenitor cell transplant in relapsed or refractory B-cell NHL. Blood 2001; 98(suppl):2835a.
46. Mehta MP, Rodrigus P, Terhaard CH, et al. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol 2003; 21:2529-2536.
47. Meyers CA, Smith JA, Bezjak A, et al. Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol 2004; 22:157-165.
48. Magda D, Lepp C, Gerasimchuk N, et al. Redox cycling by motexafin gadolinium enhances cellular response to ionizing radiation by forming reactive oxygen species. Int J Radiat Oncol Biol Phys 2001; 51:1025-1036.
49. Ketterer N, Salles G, Moullet I, et al. Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies. Br J Haematol 1998; 103:235-242.
50. Visani G, Lemoli RM, Tosi P, et al. Fludarabine-containing regimens severely impair peripheral blood stem cells mobilization and collection in acute myeloid leukaemia patients. Br J Haematol 1999; 105:775-779.
51. Laszlo D, Galieni P, Raspadori D, et al. Fludarabine containing-regimens may adversely affect peripheral blood stem cell collection in low-grade non-Hodgkin lymphoma patients. Leuk Lymphoma 2000; 37:157-161.
52. Tournilhac O, Cazin B, Leprette S, et al. Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia. Blood 2004; 103:363-365.
53. Ansell SM, Ristow KM, Habermann TM, et al. Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma. J Clin Oncol 2002; 20:3885-3890.